1. Home
  2. VHC vs IFRX Comparison

VHC vs IFRX Comparison

Compare VHC & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VirnetX Holding Corp

VHC

VirnetX Holding Corp

HOLD

Current Price

$16.33

Market Cap

79.2M

Sector

Miscellaneous

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$0.95

Market Cap

60.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VHC
IFRX
Founded
2005
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.2M
60.6M
IPO Year
2008
2017

Fundamental Metrics

Financial Performance
Metric
VHC
IFRX
Price
$16.33
$0.95
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.50
AVG Volume (30 Days)
8.9K
171.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
35.17
N/A
EPS
N/A
N/A
Revenue
$5,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,054.36
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.60
$0.71
52 Week High
$29.00
$1.94

Technical Indicators

Market Signals
Indicator
VHC
IFRX
Relative Strength Index (RSI) 45.92 52.69
Support Level $15.94 $0.75
Resistance Level $18.09 $1.16
Average True Range (ATR) 1.50 0.07
MACD 0.15 0.01
Stochastic Oscillator 47.28 50.85

Price Performance

Historical Comparison
VHC
IFRX

About VHC VirnetX Holding Corp

VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. The company's software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services and critical infrastructures.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: